[BioS] Inventera launches joint research with UCSF on Nano scaffold ADC
Predicted impact: Low
Joint research with UCSF; early-stage collaboration with no stated revenue size.
Inventera인벤테라
0007J0 · KOSDAQ · ₩0007J0 · 인벤테라
₩8,630▲ ₩140 (1.65%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −75.52%
- Market cap
- ₩68B
- Enterprise value
- ₩67B
- P/E
- —
- P/B
- 2.3×
- Dividend yield
- 0.0%
- ROE
- −26.9%
- Net margin
- —
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−85.7% from the high
₩6,090Today: ₩8,430 – ₩8,970₩60,200
Returns
- 1W−6.7%
- 1M−39.2%
- 3M+24.2%
- 6M−62.3%
- YTD−75.5%
- 1Y—
- Volume today
- 17,408
- 0.1× the 20-day average
- Traded today
- ₩150M
- Listed shares
- 7,865,714
- EPS (12 months)
- −₩1,023
- Earnings yield −11.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.IPOListed Apr 2, 2026 at ₩16,600IPO details →
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 32 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: A new research partnership with a well-known US university is a positive development. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-37.5% over the last month; the price is below its 20-day average.
- News impactSome5 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Inventera stock overview
Inventera (인벤테라, KRX: 0007J0) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops nanomedicines based on its proprietary nanostructure platform technology, Invinity™, which is a polysaccharide-based nano drug delivery system designed for diagnosis and treatment. Its shares closed at ₩8,630 on Oct 27, 2026, up 1.65% on the day, giving it a market value of ₩68B.
Key facts
- Market cap
- ₩68B
- Sector
- Biotech & Pharma
- Latest price change
- +1.65%
- As of
- Oct 27, 2026
- Main business
- The company develops nanomedicines based on its proprietary nanostructure platform technology, Invinity™, which is a polysaccharide-based nano drug delivery system designed for diagnosis and treatment.
Quick answers about Inventera
- What does Inventera do?
- The company develops nanomedicines based on its proprietary nanostructure platform technology, Invinity™, which is a polysaccharide-based nano drug delivery system designed for diagnosis and treatment. Its priority business is nano-MRI contrast agents for disease-specific diagnosis, with lead candidates INV-002 for musculoskeletal disease (in Phase 3 in Korea), INV-001 for lymphatic disease (in Phase 2a in Korea), and INV-003 for pancreaticobiliary disease (in IND-enabling studies). The company plans to sell its products directly in domestic and overseas markets while also pursuing technology transfers and joint development with global pharmaceutical companies.
- What is the market cap of Inventera?
- The market capitalisation of Inventera was ₩68B at the close on Oct 27, 2026.
- Who are the largest shareholders of Inventera?
- According to the latest official filings, the largest reported holders are Shin Tae-hyun (41.61%, as of Apr 9, 2026); Gong Eun-a (11.08%, as of Apr 9, 2026); Light Farmtech (5.91%, as of Apr 9, 2026).
- When is the next earnings report from Inventera?
- Korean companies rarely announce results dates in advance. Based on when Inventera filed the same report in past years, its next annual results is expected around Mar 31, 2027.
Company profile
The company develops nanomedicines based on its proprietary nanostructure platform technology, Invinity™, which is a polysaccharide-based nano drug delivery system designed for diagnosis and treatment. Its priority business is nano-MRI contrast agents for disease-specific diagnosis, with lead candidates INV-002 for musculoskeletal disease (in Phase 3 in Korea), INV-001 for lymphatic disease (in Phase 2a in Korea), and INV-003 for pancreaticobiliary disease (in IND-enabling studies). The company plans to sell its products directly in domestic and overseas markets while also pursuing technology transfers and joint development with global pharmaceutical companies.
Written by AI from the company's latest annual report.
- Korean name
- 인벤테라
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 신태현
- Founded
- Nov 2018
- Listed
- Apr 2026
- Listed shares
- 7,865,714
- Fiscal year ends
- Month 12
- Website
- inventera.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
G2GBIO Hits Limit-Up on China Partnership; Inventera Gains on U.S. Clinical Trial Clearance [K-Bio...
Predicted impact: Low
US Phase 1 trial approval already reported in the past 14 days; small company with no revenue.
G2GBIO Surges on Chinese Pharma Tie-Up; Inventera Gets Positive Signal on U.S. Trial [Bio Market Briefing]
Predicted impact: Low
China platform evaluation partnership already reported in the past 14 days; undisclosed value.
Recent filings
See all- Major management matter relevant to investorsOct 19, 2026
- Major management matter relevant to investorsSep 21, 2026
- Major management matter relevant to investorsSep 17, 2026
- Notice on Grant of Stock Purchase OptionsSep 4, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Inventera / 인벤테라 / 0007J0 / KRX:0007J0
Source: KRX statistical information